ISPOR 15th Annual European Congress Banner
Program: Monday, 5 November 2012
7:30 - 8:30
EDUCATIONAL SYMPOSIUM (Sponsored by CPRD)
OUTCOMES RESEARCH - A TOTAL HEALTH CARE SYSTEM APPROACH

Breakfast available prior to the presentation for symposium attendees

See Symposium Description »

8:45 - 14:15
RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
8:45-10:45
WELCOME & FIRST PLENARY SESSION
WELCOME
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President and Associate Professor, University of Calgary and University of McMaster, Director, HTA, Alberta Bone and Joint Health Institute & Canada Research Chair, Health Services and Systems Research Centers, Calgary, AB, Canada

OPENING SPEECH
Andrzej Rys, MD

Andrzej Rys, MD
Director of Health Systems and Products, European Commission, Brussels, Belgium

CONGRESS PROGRAM OVERVIEW
Wolfgang Greiner, PhD, MSc Wolfgang Greiner, PhD, MSc
Professor & Director, Department of Health Economics and Health Management
University of Bielefeld, Bielefeld, Germany
Michael Schlander, MD, PhD, MBA

Michael Schlander, MD, PhD, MBA
Professor, Health Care and Innovation Management, University of Heidelberg and Chairman & Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germany

The role of health technology assessment (HTA) in reimbursement decisions in European health systems is still in transition. In Germany, the introduction of a new regulation for reimbursement (AMNOG) will minimize the significance of health economic analysis for pricing, because a consensus could not be reached on basic methodological issues regarding cost-effective analysis. The clinical evidence provided in ‘value dossiers’ is now the basis for price negotiations between the German statutory health insurance and the pharmaceutical industry. In the UK and France, the changes in regulations are not as dramatic, but criteria for reimbursement decisions (apart from cost-effectiveness analysis) are still actively debated. In this session, the current state of these discussions will be outlined, and future trends and methodological requirements will be discussed by key leaders of health authorities and HTA agencies in Germany, France and the UK.

For more information on these European country health care systems and health care decision processes, see the ISPOR Global Health Care Systems Road Map at: http://www.ispor.org/HTARoadMaps/Default.asp and http://www.ispor.org/PEguidelines/index.asp or attend the ISPOR Short Course, “Reimbursement Systems in Europe” given prior to this First Plenary Session. See: Reimbursement Systems in Europe for more information about this ISPOR Short Course.

Wolfgang Greiner, PhD, MSc Moderator:
Wolfgang Greiner, PhD, MSc
Professor & Director, Department of Health Economics and Health Management, University of Bielefeld, Bielefeld, Germany
Jürgen Windeler, MD Speakers:
Jürgen Windeler, MD
Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Carole Longson, PhD
Director, Centre for Health Technology Evaluation and Executive Director, National Institute of Health & Clinical Excellence (NICE), London, UK
Jean-Luc Harousseau

Jean-Luc Harousseau, MD
President and Chairman of the Board, Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France

10:45 - 11:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
11:00 - 12:00
ISSUE PANELS – SESSION I
11:00 - 12:00
IP1: ROADMAP OF HTA IN EUROPE – MOVING HTA FORWARD OR JUST STUCK IN TRAFFIC? (ISPOR Invited Issue Panel)
Moderator:

J.L. (Hans) Severens, PhD, Professor of Evaluation in Health Care, Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

Panelists:

Finn Borlum-Kristensen, MD, PhD, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark; Andrzej Rys, MD, Director of Health Systems and Products, European Commission, Brussels, Belgium; Gordana Kalan Živčec, MD, Board Member, Standing Committee of European Doctors (CPME) and President of the Medical Chamber of Slovenia, Ljubljana, Slovenia

J.L. (Hans) Severens, PhD Finn Borlum-Kristensen, MD, PhD Andrzej Rys, MD Gordana Kalan Živčec, MD
J.L. Severens F. Borlum-Kristensen A. Rys G. K. Živčec
11:00 - 12:00
IP2: IS THERE SCOPE FOR MORE HARMONIZATION OF PROCEDURES FOR ASSESSING ORPHAN DRUGS IN EUROPE?
Moderator: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York and Principal Consultant, OptumInsight, Heslington, York, UK
Panelists: Amy K. O'Sullivan, PhD, Director, Health Economics and Outcomes Research, OptumInsight, Medford, MA, USA; Michael Barry, MD, PhD, Clinical Director, National Centre for Pharmacoeconomics, St. James's Hospital, Dublin, Ireland; Francis Pang, MSc, MPhil, Senior Director of Market Access and Public Affairs, Shire Human Genetic Therapies, Basingstoke, UK
11:00 - 12:00
IP3: HOW TRANSFERABLE IS CLINICAL EVIDENCE: DOES ONE-SIZE FIT ALL WHEN ASSESSING THE RELATIVE EFFECTIVENESS OF PHARMACEUTICALS IN EUROPE?
Moderator:

Keith Abrams, MSc, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, United Kingdom

Panelists:

Panelists: Antje Behring, PhD, Desk Officer, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany; Elisabeth George, PhD, Associate Director, Technology Appraisals, National Institute for Health and Clinical Excellence, London, UK; Clare McGrath, PhD, Global Head, HTA Policy, AstraZeneca, Greater Manchester, UK

11:00 - 12:00
IP4: HOW IS IQWIG MEETING THE CHALLENGES OF THE NEW GERMAN HEALTH CARE REFORM?
Moderator: Alric Ruether, MD, PhD, Head, Department of Health Care Quality, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Panelists:

Andreas Gerber, PhD, MD, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, Stefan Sauerland, MD, MPH, Head, Department of Non-Drug Interventions, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; TBD, German Ministry of Health, Berlin, Germany; Jos Kleijnen, MD, PhD, Owner, Kleijnen Systematic Reviews, Professor, Systematic Reviews in Health Care, Maastricht University and Clinical Professor, Joanna Briggs Institute, Faculty of Health Sciences, University of Adelaide, York, UK

11:00 - 12:00
IP5: POLICY STRATEGIES UNDER AUSTERE CONDITIONS IN EUROPEAN COUNTRIES - DOING LESS WITH LESS AT WHAT COST? (ISPOR Invited Issue Panel)
Moderator:

Carolin Miltenburger, PhD, Senior Director, Global Health Economics & Reimbursement, Medtronic, Tolochenaz, Switzerland

Panelists:

László Gulácsi, MD, PhD, Professor, Head, Health Economics and Health Technology Assessment Research Centre, HunHTA, Corvinus University of Budapest, Budapest, Hungary; Mary Geitona, PhD, Professor, School of Social Policy, University of Peloponnese, Korinth, Greece; Pedro Pita Barros, PhD, Professor of Economics, Nova School of Business and Economics, Lisbon, Portugal; Niek S. Klazinga, MD, PhD, Professor & Chair, Department of Social Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands and Senior Policy Advisor & Head, Health Care Quality Indicator Programme, Organization for Economic Co-Operation and Development (OECD), Paris, France

C. Miltenburger László Gulácsi, MD, PhD Mary Geitona, PhD Pedro Pita Barros, PhD Niek S. Klazinga, MD, PhD
C. Miltenburger L. Gulácsi M. Geitona P. P. Barros N. S. Klazinga
12:00 - 14:15
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
12:15 - 13:15
EDUCATIONAL SYMPOSIUM (Sponsored by EuroQol Group)
New research for future approaches to measuring and valuing health
13:15 - 14:15
POSTER AUTHOR DISCUSSION HOUR – SESSION I
14:15 - 15:15
Research Poster Presentations Hall Closed
14:15 - 15:15
RESEARCH PODIUM PRESENTATIONS – SESSION I
14:15 - 15:15

DIABETES OUTCOMES RESEARCH

DB1

ASSESSING THE RELATIONSHIP BETWEEN THE EFFECT OF GLYCEMIC CONTROL AND AVOIDED SYMPTOMATIC HYPOGLYCEMIA ON QUALITY OF LIFE IN THE MANAGEMENT OF TYPE 2 DIABETES

 

Foos V1, McEwan P2, Lloyd A3, Palmer JL4, Lamotte M5, Grant D3
1IMS Health, Basel, Basel-Stadt, Switzerland, 2HEOR Consulting, Monmouth, Monmouthshire, UK, 3IMS Health, London, UK, 4IMS Health, Allschwil, Basel-Landschaft, Switzerland, 5IMS Health, Vilvoorde, Belgium

14:15 - 15:15

DB2

ECONOMIC CONSEQUENCES OF SEVERE HYPOGLYCAEMIA – PRELIMINARY FINDINGS FROM FIVE CENTRAL EUROPEAN COUNTRIES

 

Niewada M1, Jakubczyk M1, Czech M2, Paweska J1, Barszcz E1
1HealthQuest Sp z o.o., Warsaw, Poland, 2Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland

14:15 - 15:15

DB3

HOW FEAR FOR HYPOGLYCEMIA INFLUENCES HEALTH-RELATED QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS PATIENTS IN SPAIN? HIPOQOL-II STUDY

 

Font B1, Lahoz R1, Roldan C1, Jódar E2, Álvarez F3, Ávila L4, Palomares R5, Lizan L6
1Novartis Farmaceutica, Barcelona, Spain, 2Hospital Universitario Quirón Madrid, Madrid, Spain, 3Centro de Salud la Calzada II, Gijón, Spain, 4Consultorio Local Almachar, Málaga, Spain, 5Hospital Reina Sofía, Córdoba, Spain, 6Universitat Jaume I, Castellon, Castellon, Spain

14:15 - 15:15

DB4

PATIENT-REPORTED HYPOGLYCAEMIA IN REAL-WORLD SETTINGS IN SEVEN EUROPEAN COUNTRIES

 

Östenson CG1, Geelhoed-Duijvestijn PHLM2, Jensen MM3, Pedersen-Bjergaard U4
1Karolinska Institutet, Stockholm, Sweden, 2Haaglanden Medical Centre, The Hague, The Netherlands, 3Novo Nordisk Scandinavia AB, København, Denmark, 4Hillerød Hospital, Hillerød, Denmark

14:15 - 15:15

EVERYTHING YOU WANTED TO KNOW ABOUT NICE

NI1

THREE YEARS OF NICE SCIENTIFIC ADVICE: COMPREHENSIVE ANALYSIS OF REQUESTS TO THE PROGRAMME

 

Phillips S1, Crowe E2, Chivers R1, Longson C1
1National Institute for Health and Clinical Excellence, Manchester, UK, 2National Institute for Health and Clinical Excellence, London, UK

14:15 - 15:15

NI2

THE USE OF OFF-LABEL COMPARATORS IN NICE APPRAISALS – AN INDIRECT ENDORSEMENT?

 

Kusel J, Wong GK
Costello Medical Consulting Ltd, Cambridge, UK

14:15 - 15:15

NI3

PATIENT ACCESS SCHEMES IN THE NEW NHS

 

Spoors J, Brown C, Johnson N, Rietveld A
RJW & Partners, Royston, Hertfordshire, UK

14:15 - 15:15

NI4

ANALYSIS OF STAKEHOLDERS INVOLVED IN HTA DECISION MAKING PROCESS IN THE UNITED KINGDOM

 

Kalbasko A1, Andreykiv M2, Van Engen A3, Zorzi O2
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Quintiles, Hoofddorp, The Netherlands, 3Quintiles Global Consulting, Hoofddorp, Noord-Holland, The Netherlands

14:15 - 15:15

PRICING, ACCESS AND REIMBURSEMENT

PR1

COMPARISON OF CANCER DRUG PRICES IN THE UNITED STATES AND THE UNITED KINGDOM

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

14:15 - 15:15

PR2

GUIDING PRINCIPLES FOR PROVIDING EFFECTIVE ACCESS TO MEDICINES IN EMERGING MARKETS

 

Shankar R, Hickson S
IMS Consulting Group, Cambridge, UK

14:15 - 15:15

PR3

DRIVERS OF PRICING AND MARKET ACCESS DECISIONS - EXAMPLES IN SELECTED COUNTRIES

 

Assimakopoulos M, Jeffery M, Mukku SR
Access Partnership, London, UK

14:15 - 15:15

PR4

TRENDS IN PRICING AND REIMBURSEMENT SCHEMES FROM 1994-2011

 

Sotak ML1, Haig JK2, Sulzicki M3
1OptumInsight Life Sciences, Chicago, IL, USA, 2OptumInsight Life Sciences, Burlington, ON, Canada, 3OptumInsight Life Sciences, Newport Beach, CA, USA

14:15 - 15:15

RESEARCH ON QUALITY OF LIFE AND PATIENT PREFERENCE METHODS

QL1

EQ-5D-5L VALUATION PROJECT FOR THE SPANISH POPULATION – A DESCRIPTIVE OVERVIEW AND PRELIMINARY RESULTS

 

Ramos-Goñi J1, Errea M2, Rivero-Arias O3, Cabasés JM2, Pinto JL4
1FUNCIS, S/C Tenerife, Canary Island, Spain, 2Public University of Navarra, Pamplona, Navarra, Spain, 3Oxford University, Oxford, UK, 4Universidad Pablo de Olavide, Sevilla, Andalucía, Spain

14:15 - 15:15

QL2

EVALUATION OF MINIMAL CLINICALLY IMPORTANT DIFFERENCES FOR HEALTH-RELATED QUALITY OF LIFE SCALES IN PARKINSON'S DISEASE

 

Winter Y, Lubbe D, Oertel W, Dodel R
Philipps University, Marburg, Hessen, Germany

14:15 - 15:15

QL3

SIMULATIONS OF ADAPTIVE MEASUREMENT OF CHANGE FOR HEALTH RELATED QUALITY OF LIFE ASSESMENTS IN CHRONIC CONDITIONS

 

Rebollo P, Castejón N, Cuervo J, Rodríguez A, Diaz H
LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain

14:15 - 15:15

QL4

THE IMPACT OF DISEASE INFORMATION ON GENERAL PUBLIC PREFERENCES FOR HEALTH STATES: COMPARING LABELING, DISEASE-SPECIFIC, AND ADAPTATION INFORMATION

 

Butt T, Morris S, Orr S, Rubin G
University College London, London, UK

14:15 - 15:15

RESOURCE USE RESEARCH

RU1

CHOLINESTERASE INHIBITORS: A POPULATION-BASED ASSESSMENT OF RESOURCE UTILIZATION AND COSTS FOR PATIENTS WITH ALZHEIMER'S DEMENTIA

 

Fong RK, Gill SS, Johnson AP
Queen's University, Kingston, ON, Canada

14:15 - 15:15

RU2

POTENTIAL TIME SAVINGS WITH TRASTUZUMAB SUBCUTANEOUS (SC) INJECTION VERSUS TRASTUZUMAB INTRAVENOUS (IV) INFUSION: RESULTS FROM INTERVIEWS CONDUCTED AS PART OF A TIME-AND-MOTION STUDY (T&M) ACROSS 17 SITES

 

De Cock E1, Tao S2, Urspruch A3, Knoop A4
1United BioSource Corporation, Barcelona, Spain, 2United BioSource Corporation, Dorval, QC, Canada, 3F.
Hoffmann-La Roche Ltd., Basel, Switzerland, 4Odense University Hospital, Odense, Denmark

14:15 - 15:15

RU3

SOME ISSUES WITH THE ICER IN TECHNOLOGY ASSESSMENTS OF SCREENING INTERVENTIONS FOR RARE CONDITIONS

 

Teljeur C, O'Neill M, Harrington P
Health Information and Quality Authority, Dublin, Ireland

14:15 - 15:15

RU4

UNIVERSAL VERSUS SELECTIVE SCREENING FOR DOWN'S SYNDROME: AN ECONOMIC EVALUATION OF RESOURCE USE AND COSTS BY SCREENING POLICY

 

Lynn FA, McNeill JA, Doran J, Alderdice FA
Queen's University Belfast, Belfast, County Antrim, UK

15:15 - 15:30
BREAK & EXHIBITS VIEWING
15:30 - 19:30
RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
15:30 - 16:30
RESEARCH PODIUM PRESENTATIONS – SESSION II
15:30 - 16:30

CARDIOVASCULAR DISEASE OUTCOMES RESEARCH

CV1

COST-EFFECTIVENESS OF A NURSE FACILITATED SELF-MANAGEMENT PROGRAMME FOR HEART FAILURE

 

Mejia A1, Richardson G2, Cockayne S2, Pattenden J2, Lewin R2
1Universidad de Antioquia, Medellín, Antioquia, Colombia, 2University of York, York, UK

15:30 - 16:30

CV2

IS IT WORTH SPENDING ANY MONEY TO DEVELOP A BIOMARKER TEST TO OPTIMIZE STATIN TREATMENT FOR INDIVIDUALS WITH AN INTERMEDIATE CARDIOVASCULAR RISK?

 

Burgers LT1, Nauta ST2, Deckers JW2, Severens JL1, Redekop WK1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands

15:30 - 16:30

CV3

OUTCOMES AND COSTS OF CONCOMITANT AORTIC VALVE REPLACEMENTS ASSOCIATED WITH A NEW SUTURELESS AND COLLAPSED VALVE IN ITALY, FRANCE, GERMANY, AND THE UNITED KINGDOM

 

Pradelli L1, Zaniolo O1, Giardina S2, Ranucci M3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Saluggia, Italy, 3IRCSS Policlinico San Donato, San Donato Milanese, Italy

15:30 - 16:30

CV4

EVALUATION OF TELEMONITORING FOR HEART FAILURE PATIENTS WITH IMPLANTABLE DEFIBRILLATORS: THE EVOLVO (EVOLUTION OF MANAGEMENT STRATEGIES OF HEART FAILURE PATIENTS WITH IMPLANTABLE DEFIBRILLATORS) STUDY

 

Zanaboni P1, Marzegalli M2, Landolina ME3, Lunati M4, Perego GB5, Guenzati G2, Curnis A6, Borghetti F7, Beccagutti G7, Borghi G8, Masella C9
1Politecnico of Milano/University Hospital of North Norway, Milano, Italy, 2San Carlo Borromeo Hospital, Milano, Italy, 3San Matteo Hospital, Pavia, Italy, 4Niguarda Hospital, Milano, Italy, 5S.
Luca Hospital - Istituto Auxologico Italiano IRCCS, Milano, Italy, 6Spedali Civili, Brescia, Italy, 7Medtronic Italia, Sesto San Giovanni, Milan, Italy, 8CEFRIEL, Regione Lombardia, Milan, Italy, 9Politecnico of Milano, Milano, Italy

15:30 - 16:30

MEDICATION ADHERENCE RESEARCH

MA1

UTILIZATION OF DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS: ANALYSIS FROM AN ITALIAN ADMINISTRATIVE DATABASE

 

Furneri G1, Scalone L2, Ciampichini R1, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2, Cesana G2, Mantovani LG3
1Charta Foundation, Milan, Italy, 2University of Milano-Bicocca, Monza, Italy, 3Federico II University of Naples, Naples, Italy

15:30 - 16:30

MA2

OBSERVATION OF PERSISTENCE RATES AND POTENTIAL COST SAVINGS ASSOCIATED WITH CERTOLIZUMAB PEGOL TREATMENT FOR RHEUMATOID ARTHRITIS IN ENGLAND, WALES AND NORTHERN IRELAND CLINICAL PRACTICE

 

Russell M1, Timoshanko J1, Smets E2, Duncan G3, Spandley A1, Roskell S4
1UCB Pharma, Slough, UK, 2UCB Pharma, Brussels, Belgium, 3Healthcare at Home Ltd, Burton on Trent, UK, 4Cannock Chase Hospital, Cannock, UK

15:30 - 16:30

MA3

PALIPERIDONE PALMITATE LONG-ACTING INJECTION FOR BRAZILIAN NON-ADHERENT SCHIZOPHRENIC PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS FROM THE PUBLIC PAYER PERSPECTIVE

 

Vitale V1, Bahmdouni LSK1, Pereira ML1, Takemoto MLS2, Fernandes RA2, Santos PML2, Morais AD1
1Janssen Cilag Farmaceutica, São Paulo, Brazil, 2ANOVA - Knowledge Translation, Rio de Janeiro, RJ, Brazil

15:30 - 16:30

MA4

ADEQUATE ADHERENCE TO INTRANASAL CORTICOSTEROIDS IS ASSOCIATED WITH SIGNIFICANTLY REDUCED NUMBER AND COSTS OF OUTPATIENT VISITS AMONG PATIENTS NEWLY DIAGNOSED WITH ALLERGIC RHINITIS

 

Buck PO1, Hankin CS2, Cox L3, Bronstone A2, Wang Z2, Lepore MS1
1Teva Pharmaceuticals, Frazer, PA, USA, 2BioMedEcon, LLC, Moss Beach, CA, USA, 3Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, USA

15:30 - 16:30

RESEARCH ON MODELING METHODS

MO1

COMPREHENSIVE DISCRETE EVENT SIMULATION MODEL FOR THE EVALUATION OF HEALTH CARE TECHNOLOGIES IN DEPRESSION

 

Toumi M1, Antonanzas F2, Hakkaart L3, Lam RW4, McCrone P5, Persson U6, Vataire AL7, Aballea S7
1University Claude Bernard Lyon 1, Lyon, France, 2University of La Rioja, Logrono, La Rioja, Spain, 3Erasmus University Rotterdam, Rotterdam, The Netherlands, 4University of British Columbia, Vancouver, BC, Canada, 5King's College London, London, UK, 6The Swedish Institute for Health Economics, Lund, Sweden, 7Creativ-Ceutical, Paris, France

15:30 - 16:30

MO2

IMPACT OF STRUCTURAL ASSUMPTIONS ON COST-EFFECTIVENESS OUTCOMES: TOWARDS A STANDARDIZED COST-EFFECTIVENESS MODEL FOR ADJUVANT BREAST CANCER THERAPIES

 

Frederix GW1, van Hasselt JG2, Schellens JH3, Hövels AM4, Huitema AD2, Raaijmakers JA5, Severens JL6
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2Slotervaart Hospital & Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Netherlands Cancer Institute & Utrecht University, Amsterdam, The Netherlands, 4Utrecht University, Utrecht, The Netherlands, 5Utrecht University & GlaxoSmithKline, Utrecht, The Netherlands, 6Erasmus University Rotterdam, Rotterdam, The Netherlands

15:30 - 16:30

MO3

LESSONS LEARNED FROM A CROSS-VALIDATION BETWEEN A DISCRETE-EVENT SIMULATION MODEL AND A MARKOV MODEL FOR PERSONALIZED BREAST CANCER TREATMENT

 

Jahn B1, Rochau U1, Arvandi M1, Kurzthaler C2, Saverno KR3, Fühne F2, Kluibenschaedl M4, Krahn M5, Paulden M6, Siebert U7
1UMIT/Oncotyrol, Hall i.T., Austria, 2Oncotyrol - Center for Personalized Cancer Medicine, Hall i. T, Austria, 4UMIT, Hall i.T., Austria/University of Utah, Salt Lake City, UT, USA, 5Department of Public Health and Health Technology Assessment, UMIT, Hall i.T., Austria, 6Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, 7University of Toronto, Toronto, ON, Canada, 8UMIT/ Oncotyrol/ Harvard University, Hall i.T., Austria

15:30 - 16:30

MO4

TREATMENT DISCONTINUATION IN ECONOMIC MODELLING OF ONCOLOGY THERAPIES: SYSTEMATIC REVIEW AND BEST PRACTICES ANALYSIS

 

Johns AMA1, Kroes MA2
1Pfizer UK, Tadworth, Surrey, UK, 2Abacus International, Bicester, Oxfordshire, UK

15:30 - 16:30

PATIENT HEALTH CARE ACCESS

PA1

ASSESSING THE PROGRESSION OF THE UK NHS HEALTHCARE REFORMS AND THE IMPACT ON HEALTH CARE DELIVERY

 

McConkey D, White R, Sewak N
Double Helix Consulting, London, UK

15:30 - 16:30

PA2

HOSPITAL-BASED HTA IN ITALY: DIFFUSION AND POTENTIAL IMPACT

 

Boscolo PR1, Ciani O2, Torbica A1
1Bocconi University, Milan, Italy, 2Peninsula Institute of Medicine and Dentistry, Exeter, UK

15:30 - 16:30

PA3

LIMITED ACCESS TO CATARACT SURGERY IN POLAND

 

Szmurlo D1, Fundament T1, Kopec G1, Brzyski D1, Wladysiuk M2, Landa K3
1HTA Consulting, Krakow, Poland, 2CEESTAHC, Krakow, Poland, 3Watch Health Care, Krakow, Krakow, Poland

15:30 - 16:30

PA4

HOME DIALYSIS: HOW HIGH CAN WE GO?

 

Laplante S1, Rutherford P2
1Baxter Healthcare Corporation, Braine l'Alleud, Belgium, 2Baxter Healthcare Corporation, Zurich, Switzerland

15:30 - 16:30

RESEARCH ON THE USE OF UTILITIES

UT1

THE CALCULATION OF QUALITY OF LIFE UTILITIES FOR ACUTE LEUKEMIA: A COMPARISON BETWEEN EQ5D-5L AND QLQ-C30

 

Leunis A1, Redekop WK2, Lowenberg B3, Uyl-de Groot C2
1Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Erasmus Medical Center, Rotterdam, The Netherlands

15:30 - 16:30

UT2

MAPPING DLQI ON EQ-5D IN PSORIASIS – TRANSFORMATION OF SKIN-SPECIFIC HEALTH-RELATED QUALITY OF LIFE INTO UTILITIES

 

Blome C1, Beikert F1, Rustenbach SJ1, Augustin M2
1University Medical Center Hamburg, Hamburg, Germany, 2University Clinics of Hamburg, Hamburg, Germany

15:30 - 16:30

UT3

ESTIMATING PREFERENCE-BASED INDEX FROM CANCER-SPECIFIC QUALITY OF LIFE MEASURES FOR USE IN COST-UTILITY-ANALYSIS

 

Teckle P, Peacock/Stuart S
Canadian Centre for Applied Research in Cancer Control, BC Cancer Agency, Vancouver, BC, Canada

15:30 - 16:30

UT4

HEALTH UTILITY SCORES IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: RESPONSE TO STIMULANT TREATMENT

 

Setyawan J1, Banaschewski T2, Hodgkins P3, Lecendreux M4, Johnson M5, Zuddas A6, Bloomfield R7, Coghill DR8
1Shire Development LLC, Wayne, PA, USA, 2University of Heidelberg, Mannheim, Germany, 3Shire Pharmaceuticals LLC, Wayne, PA, USA, 4CHU Hospital Robert-Debré, Paris, France, 5Queen Silvia Children's Hospital, Gothenburg, Sweden, 6University of Cagliari, Cagliari, Italy, 7Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom, 8Ninewells Hospital, Dundee, United Kingdom

16:45 - 17:45
WORKSHOPS – SESSION I
16:45 - 17:45
W1: USING DECOMPOSITION METHODS TO ESTIMATE HETEROGENEITY OF TREATMENT EFFECTS IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES
Discussion Leaders:

William Crown, PhD, Group President, HEOR and Late Phase Research, OptumInsight, Waltham, MA, USA; William H Olson, PhD, Leader, Research and Analysis Strategy, Janssen Pharmaceuticals, Inc., Titusville, NJ, USA

16:45 - 17:45
W2: META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY AND EFFECTIVENESS DATA: ARE THEY REALLY THE SAME?
Discussion Leaders:

Sandrine Cure, MSc, Associate Director, OptumInsight, Uxbridge, Middlesex, UK; Keith Abrams, BSc, MSc, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK; Helene Cawston, MSc, Senior Research Analyst, OptumInsight, Nanterre, France

16:45 - 17:45
W3: FUNDAMENTALS OF MODEL CALIBRATION: THEORY & PRACTICE
Discussion Leaders:

Douglas Taylor, MBA, Associate Director, Health Economics & Outcomes Research, Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA; Ankur Pandya, PhD, Assistant Professor, Department of Public Health, Weill Cornell Medical College, New York, NY, USA; David Thompson, PhD, Senior Vice President & Head of Emerging Business, Quintiles Outcome, Cambridge, MA, USA

16:45 - 17:45
W4: DRUG DEVELOPMENT TOOL (DDT) QUALIFICATION BY THE EMA AND FDA: PURPOSE, PROCEDURES, CHALLENGES, AND OPPORTUNITIES
Discussion Leaders:

Margaret Vernon, PhD, Research Scientist, United BioSource Corporation, London, UK; Nancy Kline Leidy, PhD, Senior Vice President of Scientific Affairs, Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; Brigitta U. Monz, MD, PhD, Head Global Health Economics & Outcomes Research, Corporate MAPOR, Boehringer Ingelheim GmbH, Ingelheim, Germany

16:45 - 17:45
W5: UNPLANNED EVIDENCE: IMPLICATIONS OF INVESTIGATOR-INITIATED TRIALS (IIT)
Discussion Leaders:

Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York City, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow, European Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK; Mónica Martín de Bustamante, AB, BE, Managing Director, Europe, Middle East, and Africa, CBPartners, Basel, Switzerland

16:45 - 17:45
W6: THE ART AND SCIENCE OF EXPERIMENTAL DESIGN - APPLYING THE RECOMMENDATIONS OF THE ISPOR CONJOINT ANALYSIS EXPERIMENTAL DESIGN TASK FORCE
Discussion Leaders:

F. Reed Johnson, PhD, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Axel C. Mühlbacher, PhD, Professor for Health Economics and Health Care Management, IGM Institute, Hochschule Neubrandenburg, Neubrandenburg, Germany; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada; John FP Bridges, PhD, AssociateProfessor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

17:45 - 19:30
EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
18:00 - 19:00
ISPOR FORUMS – SESSION I
18:00 - 19:00
HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL STUDIES

Web based assessment tools for prospective and retrospective observational studies for health care decision makers will be discussed. Presented by the ISPOR/AMCP/NPC ER-CI: Interpreting Prospective and Retrospective Observational Studies for Health Care Decision Makers Task Forces

Moderator/Speakers: Marc Berger, MD, Chair, CER-CI Interpreting Prospective Observational Studies for Health Care Decisions Task Force and Executive Vice President & Senior Scientist, OPTUMInsight, New York, NY, USA; Bradley Martin, PhD, RPh, PharmD, Chair, CER-CI Interpreting Retrospective Observational Studies for Health Care Decisions Task Force and Professor & Division Chair, College of Pharmacy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR, USA

18:00 - 19:00
HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR NETWORK META ANALYSIS STUDIES

A web based assessment tool for network meta analysis studies for health care decision makers will be discussed. Presented by the ISPOR/AMCP/NPC CER-CI: Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force

Speaker: Jeroen Jansen, PhD, Chair, CER-CI Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force and Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA

18:00 - 19:00
ECONOMIC ASSESSMENT IN SPAIN: LESSONS TO BE LEARNED AND POSSIBILITIES FOR THE FUTURE

Recently published legislation, such as the Real Decreto Law, 16/2012, emphasizes once again that economic evaluation is one of the criteria to be considered in the incorporation of new technologies. In this law, and in others, declarations and notifications by the Ministry note the necessity to consolidate and support economic evaluation through the use of agency and expert committee networks. However, there is uncertainty about the process and the true roles and responsibilities of the possible players involved. This uncertainty is compounded by the recent proposal to close one of the regional HTA agencies, Agencia Lain Entralgo, in Madrid.

To reduce this uncertainty, it is necessary to promote and establish discussion forums to analyze the lessons learned from past experiences, and to suggest possible future models to enable health technology assessment to be consolidated and used as a criteria to incorporate new health care technologies in the Spanish National Health Care System. During this forum the current status and possible future models will be discussed. Presented by the ISPOR Spain Regional Chapter

Moderator: Olga Espallardo, MBA, MSc, Health Economics, Services & Policies Executive Manager, Johnson Medical Iberia, Madrid, Spain

Speakers: Javier Mar Medina, MD, Chief of the Health Management Unit, Hospital Alto Deba, Mondragon, Spain; Juan Manuel Ramos Goñi, Researcher, HTA Unit of Canary Islands Health Service, Santa Cruz de Tenerife, Spain; Carme Piñol, MD, MSc, Principal PMA and HE, IMS Health, Barcelona, Spain; Ana Ortega, PhD, GENESIS Group, Spanish Society for Hospital Pharmacy, Pamplona, Spain; Melany Worbes Cerezo, MSc, Health Economics, Market Access & Reimbursement Manager CV & Metabolics Europe, Middle East & Africa Janssen, Madrid, Spain

18:00 - 19:00
IMPLEMENTATION OF HTA TO SUPPORT PRICING AND REIMBURSEMENT DECISIONS IN EMERGING MARKET COUNTRIES: MORE ACADEMIC, MORE PRAGMATIC OR "NICER" APPROACH?

The NICE approach has become the gold standard of HTA implementation in pricing and reimbursement decisions. However, it is difficult to replicate the same approach in smaller and middle income countries due to limitations of human and financial resources for HTA and lack of traditions and political commitment to improve the transparency of public policy decisions. There are two major approaches for HTA implementation to support pricing reimbursement decisions in emerging markets. In some countries capacity building is the first step, and HTA is mainly driven by academic groups. In other countries cost-effectiveness and budget impact have become mandatory criteria in pharmaceutical reimbursement decisions without having sufficient capacity for high quality HTA research. This forum will discuss the pros and cons of both approaches from the perspective of middle income countries, such as: Bosnia-Herzegovina, Hungary, Republic of Macedonia, and Israel. Presented by the ISPOR Bosnia-Herzegovina, Hungary, Israel, Republic of Macedonia and Serbia Chapters

Moderator: Zoltán Kaló, MSc, MD, PhD, Director, Health Economic Research Center, Department of Health Policy and Health Economics, Associate Professor of Social Sciences Eötvös Loránd University (ELTE) and Founder & CEO, Syreon Research Institute , Budapest, Hungary

Speakers: Tarik Čatić, MSc Pharm, President, ISPOR Bosnia-Herzegovina Regional Chapter, Sarajevo, Bosnia and Herzegovina ; Ljubica Suturkova, PharmD, PhD, President, ISPOR Republic of Macedonia Regional Chapter and Professor of Faculty of Pharmacy, UKIM, Skopje, Republic of Macedonia; Nicky Liebermann, MD, Head of Community Medical Division, Clalit Health Services, Tel-Aviv, Israel; Vlad Zah, Phd (c), Health Economist, Beograd, Serbia

18:00 - 19:00
THE SOCIO-ECONOMIC IMPACT OF HEALTH CARE COST-CONTAINMENT MEASURES DURING ECONOMIC CRISIS IN THE EUROPEAN UNION (EU)

Due to the financial crisis, many EU countries were led into the implementation of cost-containment measures in health care , focusing primarily on pharmaceutical consumption and expenditure. Until recently, many demand side measures were implemented, impacting pricing, manufacturers and health care provider's profits. This forum will provide an overview of health care cost-containment measures in several emerging European markets, such as Bulgaria, Czech Republic and Greece and their impact on access to medicines. The economic impact of cost-containment measures imposed on patients, as well as social insurance funds will be presented. Presented by the ISPOR Bulgaria, Czech and Greece Chapters

Moderator: Magdalini Chatzikou, PhD, Senior Health Economics Manager, Novartis, Athens, Greece

Speakers: Guenka Petrova, MPharm, MEcon, PhD, DSc, President, ISPOR Bulgaria Regional Chapter and Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria Jana Skoupa, MD, MBA, 1st Medical Faculty Member, Medical Data Center, Charles University, Prague, Czech Republic; Mary Geitona, MSc, PhD, President, ISPOR Greece Regional Chapter and Associate Professor, Health Economics and Social Policy, School of Social Policy, University of Peloponnese, Greece

18:00 - 19:00
INTERNATIONAL HTA EXPERIENCE AND POSSIBLE HTA MODELS IN RUSSIA AND NEIGHBORING COUNTRIES

This forum will focus on assessment of medical technologies in Armenia, Belarus, Kazakhstan, Russia, and Ukraine. How assessment is being developed and implemented in each country; the use of HTA instruments in building drug insurance models; reference pricing; and the obstacles and possible solutions common to all the countries will be discussed. Presented by ISPOR Russia HTA, Armenia, Belarus, Kazakhstan, and Ukraine Chapters.

Moderator/Speaker: Vitaly Omelianovsky, MD, PhD, DSc, Professor, Chairman of the Board, National Center for Technology Assessment in Health Care and Deputy Director, Center for Monitoring and Clinical & Economic Evaluation, Rozdravnadzor, Moscow, Russia

Speakers: Maria Avxentyeva, MD, PhD, DSc, Senior Researcher, National Center for Technology Assessment in Health Care, Moscow, Russia; Olha Zaliska, DSci (Pharm), PhD, Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine; Viacheslav Tolubaiev, MD, PhD(c) and Senior Researcher, Farmak, Kyiv, Ukraine; Vladimir A. Matveev, MD, Professor, Pediatrics Department, Vitebsk State Medical University, Vitebsk, Belarus; Alexandr Kostyuk, MD, PhD, Head of Centre of Standardization and Health Technologies Assessment, Federal Centre for Health Development, Astana, Kazakhstan; Arpine Mikayelyan, MS, PharmD, Specialist in Pharmacoeconomics, Darmantest Laboratories (DTL), Yerevan, Armenia

18:30 - 19:30
POSTER AUTHOR DISCUSSION HOUR – SESSION II